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Patient reported out-
comesAbstract Background: The TACT trial (CRUK/01/001) compared adjuvant sequential FEC-
docetaxel (FEC-D) chemotherapy with standard anthracycline-based chemotherapy of similar
duration in women with early breast cancer. Results at a median of 5 years suggested no
improvement in disease-free survival with FEC-D. Given differing toxicity proﬁles of the
regimens, the impact on quality of life (QL) was explored.
Methods: Patients from 44 centres completed standardised QL questionnaires before chemo-
therapy, after cycles 4 and 8, at 9, 12, 18 and 24 months and at 6 years follow-up. Patient dia-
ries assessed frequency, associated distress and impact on daily activity of 15 treatment related
side effects.
Findings: 830 patients (415 FEC-D; 415 controls) contributed assessments during 0–24 months;
362 of whom participated again at 6 years. During chemotherapy, FEC-D impaired global
health/QL and depression rates and signiﬁcantly more QL domains than standard regimens.
Novel diary card ratings highlighted signiﬁcantlymore distress and interference with daily activ-
ities due to FEC-D side effects compared with standard treatment. In both groups, most QL
parameters returned to baseline levels by 2 years and were unchanged at 6 years.
2376 E. Hall et al. / European Journal of Cancer 50 (2014) 2375–2389Interpretation: Within expected negative effects of chemotherapy on wide ranging QL domains
FEC-D patients reported greater toxicity, disruption and distress during treatment with no
improvement in disease outcome at 5 years than patients receiving standard anthracycline-based
chemotherapy. Findings should inform future patients of relative costs and beneﬁts of adjuvant
chemotherapy.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
The toxicity experienced by women with early breast
cancer undergoing adjuvant chemotherapy concerns
both patients and clinicians, especially when more inten-
sive, toxic regimens result in small or no overall survival
gains. In meta-analyses of randomised controlled trials
[1] comparing taxane-containing chemotherapy with
control regimens of similar duration, results showed
no statistically signiﬁcant reduction in the risk of recur-
rence (relative risk (RR): 0.96, standard error (SE):0.05;
p > 0.1) or death (RR: 0.96, SE: 0.06; p > 0.1). These
analyses were heavily inﬂuenced by the UK Taxotere
as Adjuvant Chemotherapy Trial (TACT, CRUK/01/
001, ISRCTN79718493) [2] which, with median
62 months follow-up, did not demonstrate an overall
gain in disease-free (hazard ratio (HR): 0.95, 95% CI:
0.85–1.08) or overall survival (HR: 0.99 (0.86–1.14)).
In this context the prospective assessment of patient
reported toxicity and quality of life (QL) incorporated
in TACT is particularly important although its rele-
vance extends to other clinical scenarios where a small
incremental beneﬁt for taxane based regimens has been
seen [1].
The impact of adjuvant chemotherapy on QL is
widely recognised. However, the assessment of taxane
toxicity in breast cancer clinical trials has been based lar-
gely on clinical assessments [2–10] and considered
‘acceptable’ [5], ‘tolerable’ [3] or ‘manageable’ [9] when
it is known that some clinicians’ ratings of key symp-
toms and distress may not reﬂect those of patients [11–
14]. Nevertheless, health professionals increasingly
acknowledge that diﬀerences in toxicity proﬁles poten-
tially inﬂuence choice of adjuvant treatment [3], and that
there is a need to improve the QL of patients receiving
taxanes and better identify those more likely to beneﬁt
from treatment, to justify the trade oﬀ with toxicity
[6–8]. Others have argued that toxicity is transient and
some women may accept acute toxicity for the chance
of a small survival beneﬁt [15,16]. However, longer term
eﬀects from chemotherapy, such as hot ﬂushes, amenor-
rhoea and sexual dysfunction have also been consis-
tently reported [17], especially following a menopausal
transition [18]. Patient preferences are highly variable
and so discussion of treatment options should be
informed by patient reported outcomes of the impact
of treatment on QL so that expectations are realistic.In an era where the duration of adjuvant therapy and/
or accompanying toxicity has increased, even ‘transient’
treatment eﬀects can extend over 6 months.
The TACT QL sub-study provides a randomised
comparison of patient evaluated treatment related side
eﬀects in terms of severity, distress and disruption as
well as the impact on a range of QL parameters, during
treatment and over 6 years follow-up.
2. Methods
2.1. Patients
Details of the TACT trial patient population, treat-
ment regimens and procedures were previously reported
[2]. Brieﬂy, women with operable invasive breast cancer
who had undergone complete tumour excision and were
to be prescribed adjuvant chemotherapy were eligible.
Participating centres chose at the outset of the trial
whether to participate in the QL sub-study. To minimise
bias, centres were encouraged to oﬀer the QL sub-study
to all TACT patients able to read and understand
English. Speciﬁc informed consent for the QL sub-study
was obtained.
2.2. Procedures
2.2.1. Treatment
Women were randomised to receive ﬂuorouracil600/
epirubicin60/cyclophosphamide600 for four cycles fol-
lowed by docetaxel100 for four cycles (FEC-D) or one
of two standard regimens (choice declared by each cen-
tre at trial outset): F600E60C600 for eight cycles (FEC) or
epirubicin100 for four cycles followed by cyclophospha-
mide600x2/methotrexate40x2/ﬂuorouracil600x2 for four
cycles (E-CMF) [19]. Women receiving E-CMF had a
slightly longer overall duration of treatment as CMF
was given over four-weekly cycles (all other cycles given
over three weeks). Following chemotherapy, tamoxifen
was prescribed for 5 years in patients with oestrogen
receptor and/or progesterone receptor positive tumours,
or (from 2005) an aromatase inhibitor could be
prescribed according to local policy. Radiotherapy
commencing within four weeks of completion of chemo-
therapy was mandatory after breast conserving surgery
and according to local clinical guidelines following
mastectomy.
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Consenting women completed a baseline QL ques-
tionnaire booklet, administered by their hospital team
in the outpatient clinic, before randomisation. Subse-
quent booklets were mailed by ISD Cancer Clinical
Trials Unit Scotland (CaCTUS) for completion at home
(after checking the individual’s health status with their
hospital team or family doctor), after cycles 4 and 8 of
chemotherapy, then at 9, 12, 18 and 24 months. A single
prompt was made if booklets were not returned within
8 weeks.
QL was evaluated using the EORTC (European
Organisation for the Research and Treatment of Can-
cer) general cancer scale QLQ-C30 [20] and breast can-
cer module, BR23 [21]. The QLQ-C30 comprises ﬁve
functional subscales (physical, role, emotional, cogni-
tive, social), three symptom subscales (fatigue, nausea/
vomiting, pain), ﬁve symptom items and one item
reporting ﬁnancial diﬃculties. Questionnaire items had
a 4-point response format (not at all, a little, quite a
bit, very much). Two items captured global health and
global QL, each rated on a 7-point numeric scale. The
BR23 comprises four functional subscales/items (body
image, sexual functioning, sexual enjoyment, future per-
spective) and four symptom subscales/items including
systemic side eﬀects. Anxiety and depression were mea-
sured using the Hospital Anxiety and Depression Scale
(HADS) [22].
A trial speciﬁc patient self-report diary (see web
appendix) was constructed and piloted, based on a pro-
totype developed for cancer trials [23,24]. Patients rated
the extent to which side eﬀects of anthracycline and tax-
ane-based chemotherapy were experienced (rated daily)
and/or caused distress or interfered with daily activities
(rated once for each cycle assessed); all 14 items were
rated on a 4-point scale (not at all, a little, quite a bit,
very much). Diary cards were administered by the hospi-
tal for completion on days 1–21 of cycles 1, 5 and 8 and
mailed by patients to CaCTUS. At 9, 12, 18 and
24 months post-randomisation the same diary card
items concerning distress and interference of side eﬀects
were incorporated into the QL booklet.
In a separate but related initiative, patients who were
disease-free and continuing in follow-up at 6 years were
invited to participate in a cross-sectional QL assessment
focusing on residual systemic therapy eﬀects in the sur-
vivorship context (to be reported separately). Data from
patients who also participated in the original QL sub-
study were included in the longitudinal analyses
reported here.
2.3. Endpoints
The co-primary endpoints were EORTC QLQ-C30
global health/QL and psychological distress (HADS
anxiety and depression subscales). Secondary endpointsincluded other subscales and items of speciﬁc interest
from the EORTC questionnaires (including fatigue,
pain, nausea/vomiting and systemic side eﬀect subscales)
and patient diaries.
2.4. Scoring and statistical analysis
EORTC questionnaires were scored according to
standard procedures [25]. Change from baseline values
on any subscale was considered clinically relevant with
a diﬀerence of P10 [26] and statistically signiﬁcant if
p 6 0.05 (primary endpoints) or p 6 0.01 (all other
endpoints).
Recommended threshold scores for HADS anxiety
and depression were used: scoresP 11 indicated proba-
ble case disorder, scores 8–10 indicated borderline disor-
der and scores < 8 were considered normal. Prevalence
rates refer to borderline and probable case categories
combined.
The study design included at least 500 patients, with
an approximate 5% attrition rate, providing 97% power
to detect diﬀerence of 20% or more in any proportion
(1% signiﬁcance) and 78% power for diﬀerences of
15% or, alternatively, 90% power to detect a standard-
ised diﬀerence of 0.35 (1% signiﬁcance). Due to rapid
accrual to the main trial the ﬁnal size of the sample
was larger than originally anticipated, increasing the
power of comparisons.
Analyses comparing FEC-D to control were accord-
ing to intention-to-treat, adjusted for centre’s choice of
standard control regimen. Dichotomised outcomes were
adjusted for baseline score and analysed by logistic
regression (with odds ratios (OR) reported). Subscale
scores were compared between randomised groups using
analysis of covariance with change from baseline
adjusted for baseline scores. Mean diﬀerences in change
from baseline (FEC-D  control) are reported with 95%
(primary endpoints)/99% (secondary endpoints) conﬁ-
dence intervals. Categorised anxiety and depression sub-
scale scores were compared using generalised ordinal
logistic regression [27]. Treatment side eﬀects (diary card
data) were analysed by Cochran–Mantel–Haenszel test
(no baseline data were available for adjustment). Time
points for formal analysis were cycle 8, and 9 and
24 months from randomisation. Generalised estimating
equations were used for longitudinal analysis. These
models (not shown) gave similar results to single time
point analyses. Subgroup analyses by centre’s choice
of control regimen (i.e. comparing FEC-D to FEC and
FEC-D to E-CMF), menopausal status and sensitivity
analyses assessing robustness to missing data and time
windows of questionnaire response and excluding ques-
tionnaires completed after a disease event (not shown)
were consistent with the main analysis results unless
otherwise stated. Analyses were conducted in STATA
v10.1.
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TACT (ISRCTN79718493), including the QL sub-
study, was approved by the national South East
Multi-Research Ethics Committee (MREC00/1/59)
and the local ethics committees of all participating
centres. The Cancer Research UK funded Clinical Trials
and Statistics Unit (ICR-CTSU) at The Institute of
Cancer Research had overall responsibility for trial
co-ordination and undertook all statistical analyses; a
central QL co-ordinator at CaCTUS was responsible
for QL project management.2.6. Role of the funding sources
TACT was funded by Cancer Research UK (C1491/
A2645, C1491/A4129, C1491/A6852, C1491/A9895)
and educational grants from collaborating pharmaceuti-
cal companies: Sanoﬁ-Aventis, Pﬁzer and Roche. Fund-
ers had no role in study design, collection, analysis,
interpretation of data, or writing of the report. All
authors had access to study data and the corresponding
author had ﬁnal responsibility for the decision to submit
for publication.3. Results
Between July 2001 and August 2002, 830 women (415
FEC-D; 415 Control), from 44 UK centres, entered the
QL sub-study (Fig. 1). 797/830 (96.0%) patients
returned a baseline questionnaire and form the primary
analysis population. Questionnaire return rates were
high (Fig. 1) although decreased over the 2 years to
78.9% (control) and 79.1% (FEC-D). Diary card return
rate during treatment was 57.8%, 58.3% and 55.3% for
cycles 1, 5 and 8, respectively increasing to 78.9% at
9 months and 69.9% at 2 years. At 6 years, 349/538
(64.9%) patients (171 control; 178 FEC-D) completed
QL booklets.
Baseline characteristics of QL patients (Table 1) were
similar to those of the 540 TACT patients at centres par-
ticipating in the QL substudy who were ineligible, not
approached or chose not to enter the QL substudy.3.1. Global health/QL and psychological distress
Patients’ ratings showed a clinically relevant impair-
ment of global health/QL during treatment, which was
statistically signiﬁcantly worse for the FEC-D group
compared with controls at cycle 8 (mean diﬀerence in
change from baseline: 6.32 (95% CI: 9.42 to
3.23), p < 0.0001) (Fig. 2). This diﬀerence was consis-
tent when FEC-D was compared with each control reg-
imen separately (test for heterogeneity: p = 0.95).
Recovery to baseline levels occurred for women in both
regimens by 12 months and scores were similar andunchanged from baseline at 2 and 6 years (Fig. 2). Anx-
iety prevalence was greatest (44.3%) pre-treatment
reducing over time to aﬀect 30–35% women post-treat-
ment with no signiﬁcant diﬀerences between the regi-
mens (Fig. 3). In contrast, depression aﬀected 11.9%
women at baseline but increased during treatment
(Fig. 3) and was signiﬁcantly worse for FEC-D patients
compared with controls at cycle 8 (30.6% versus 23.9%;
OR = 1.63 (1.11–2.39), p = 0.01). No diﬀerences were
seen at later time points and there was no evidence of
heterogeneity by control regimen. The prevalence of
anxiety remained greater than depression throughout
follow-up.3.2. General treatment side eﬀects
Patients’ ratings of general treatment toxicity are
reﬂected in the BR23 systemic side eﬀects subscale and
the QLQC30 fatigue, pain and nausea and vomiting
symptom subscales (Fig. 2). A clinically relevant
increase in systemic side eﬀects was shown for control
and FEC-D regimens from baseline to mid treatment.
At cycle 8 this increase was signiﬁcantly greater for
FEC-D patients (mean diﬀerence in change from base-
line 4.02, 99% CI: 0.33–7.72, p = 0.005) with no evidence
of heterogeneity by control regimen (p = 0.87). Fatigue
and pain were also worse in FEC-D patients at cycle 8
whilst control patients reported more nausea and vomit-
ing (Fig. 2).
In terms of individual systemic side eﬀects, at cycle 8,
the odds of rating BR23 symptom items as ‘quite a bit’
or ‘very much’ were signiﬁcantly greater in the FEC-D
group for diﬀerent taste and sore/watery eyes; odds of
reporting hot ﬂushes and dry mouth were signiﬁcantly
greater in control patients (web appendix Table 1a and
b). All systemic eﬀects except dry mouth reduced simi-
larly in both treatment groups over follow-up to
24 months but did not recover to baseline levels. Odds
of reporting dry mouth at 2 years were greater in control
than FEC-D patients (OR = 0.34 (0.13–0.86),
p = 0.003). Moderate or marked hot ﬂushes were preva-
lent and persistent for patients in both regimens, increas-
ing from 18.4% FEC-D and 12.5% control at baseline to
38.9% and 46.7% respectively at cycle 8; levels peaked at
9 months (58.2% and 48.6% respectively) aﬀecting
around 50% women to 2 years and were reported by
more than a quarter of women at 6 years (web appendix
Table 1a).3.3. Pattern of QL changes over time
Patients’ self-reports of other QL domains mirrored
those of their side eﬀects, with clinically relevant
worsening of multiple QL domains for both FEC-D
and control regimens (Fig. 2). Statistically signiﬁcant
diﬀerences in subscale change scores between the
Fig. 1. Study proﬁle.
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functional disruption in the FEC-D regimen (Fig. 2) but
diﬀerences were not considered clinically relevant. Most
QL subscale scores improved post treatment to near
baseline values, although women’s ratings of their body
image and sexual functioning took longer to resolve. No
further changes were observed at 6 years.3.4. Diary cards: impact of treatment on side eﬀects
Patients’ diary ratings provided new insight into the
prevalence and impact of a large range of speciﬁc treat-
ment-related side eﬀects (Fig. 4, Tables 2 and 3). First, a
wide variability in the proportion of women rating
‘quite a bit’ or ‘very much’ experience of individual side
Table 1
Baseline characteristics by randomised group.
Control (N = 415) FEC-D (N = 415) Total (N = 830)
N % N % N %
Control arm FEC 268 64.6 271 65.3 539 64.9
E-CMF 147 35.4 144 34.7 291 35.1
Age (years) Mean (SD) 47.7 (8.7) 49.5 (8.4) 48.6 (8.6)
<40 96 23.1 65 15.7 161 19.4
40–49 145 34.9 131 31.6 276 33.3
50–59 143 34.5 176 42.4 319 38.4
60+ 31 7.5 43 10.4 74 8.9
Menopausal status Post-menopasual 187 45.1 218 52.5 405 48.8
Not menopausal (i.e. pre or peri) 228 54.9 197 47.5 425 51.2
Ethnicity White 391 94.2 394 94.9 785 94.6
Other 15 3.6 16 3.9 31 3.7
Not known 9 2.2 7 1.7 16 1.9
Type of surgery Mastectomy 210 50.6 225 54.2 435 52.4
Local excision 205 49.4 190 45.8 395 47.6
Radiotherapy given Yes 357 86.0 354 85.3 711 85.7
No 44 10.6 39 9.4 83 10.0
Not known 14 3.4 22 5.3 36 4.3
Nodal status Positive 332 80.0 333 80.2 665 80.1
Negative 83 20.0 82 19.8 165 19.9
Tumour grade I 19 4.6 21 5.1 40 4.8
II 149 35.9 140 33.7 289 34.8
III 246 59.3 251 60.5 497 59.9
Not known 1 0.2 3 0.7 4 0.5
Tumour size <2 cm 227 54.7 226 54.5 453 54.6
2–5 cm 143 34.5 146 35.2 289 34.8
>5 cm 45 10.8 43 10.4 88 10.6
Not known 0 0.0 0 0.0 0 0.0
Oestrogen receptor (ER) status Positive 279 67.2 275 66.3 554 66.7
Negative 136 32.8 140 33.7 276 33.3
Progesterone receptor status Positive 99 23.9 93 22.4 192 23.1
Negative 96 23.1 94 22.7 190 22.9
Not known 220 53.0 228 54.9 448 54.0
Endocrine therapy received None (ER negative) 136 32.8 140 33.7 276 33.3
Tamoxifen only 173 41.7 186 44.8 359 43.3
Aromatase inhibitor (AI) only 18 4.3 6 1.4 24 2.9
Tamoxifen and switched to AI 78 18.8 78 18.8 156 18.8
None (ER positive) 10 2.4 5 1.2 15 1.8
HER2 status Negative 290 69.9 281 67.7 571 68.8
Positive 80 19.3 91 21.9 171 20.6
Positive and received Herceptin 7 1.7 6 1.4 13 1.6
Not known 45 10.8 43 10.4 88 10.6
Combined ER/HER2 status ER+/HER2+ 44 10.6 47 11.3 91 11.0
ER+/HER2 205 49.4 198 47.7 403 48.6
ER+/HER2 not known 30 7.2 30 7.2 60 7.2
ER-/HER2+ 36 8.7 44 10.6 80 9.6
ER-/HER2 85 20.5 83 20.0 168 20.2
ER-/HER2 not known 15 3.6 13 3.1 28 3.4
EORTC QLQ-C30 Global health/QL median (IQR) 75 (58.3, 83.3) 75 (58.3, 83.3) 75 (58.3, 83.3)
HADS anxiety Normal (<8) 222 53.5 233 56.1 455 54.8
Borderline disorder (8–10) 86 20.7 83 20.0 169 20.4
Probable case disorder (P11) 105 25.3 94 22.7 199 24.0
Not known 2 0.5 5 1.2 7 0.8
HADS depression Normal (<8) 359 86.5 364 87.7 723 87.1
Borderline disorder (8–10) 37 8.9 32 7.7 69 8.3
Probable case disorder (P11) 16 3.9 14 3.4 30 3.6
Not known 3 0.7 5 1.2 8 1.0
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Fig. 2. Change from baseline in EORTC QLQ-C30 and BR23 functional and symptom subscales scores at each time point. Text shows mean
diﬀerence in change from baseline (FEC-D minus control, with conﬁdence interval and p value) at cycle 8. Red = FEC-D, blue = control.
Change from baseline scores are adjusted for baseline score, chosen control and randomised treatment group using an analysis of covariance
(ANCOVA) model. *Positive change from baseline indicates a worsening of symptoms; otherwise deterioration in function is shown by a negative
change score. 95% conﬁdence interval is given for the primary endpoint of global health/QL, 99% conﬁdence intervals for all other subscales. (For
interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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Fig. 3. HADS anxiety and depression ratings (probable case disorder, borderline disorder, normal) by regimen at each time point. Graph shows
predicted probabilities from generalised ordinal logistic regression models adjusting for baseline score, chosen control and randomised treatment.
Number of observations at each time point are given in parentheses.
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and the lowest for diarrhoea. Second, the pattern of side
eﬀect frequency over each cycle was similar for each
treatment group (Fig. 4) but signiﬁcantly more patients
in the FEC-D group experienced moderate or marked
eﬀects compared with controls. Third, novel observa-
tions showed that at cycle 8 the FEC-D regimen
accounted for signiﬁcantly increased distress and/or
interference with activities, rated by patients as ‘quite
a bit’ or ‘very much’ for eight side eﬀects (skin changes,
tingling hands/feet, tiredness, breathlessness, swollen
hands/feet, nail changes, muscle/joint pains and pain-
ful/gritty eyes); women in the control group rated signif-
icantly worse distress and/or interference in activities
from nausea and vomiting (Tables 2 and 3). Subgroup
analyses by centre’s choice of control regimen had min-
imal eﬀect on overall ﬁndings (see web appendix Tables
2a,b and 3a,b); the only statistically signiﬁcant interaction
between randomised treatment and centre’s choice of
control regimen was for diarrhoea at cycle 8 (FEC-D
more distress than FEC but FEC-D less distress than
E-CMF).
Peak severity of side eﬀects was mainly at cycle 8 but
earlier for sore mouth, nausea and mouth ulcers. Ofnote, there was persistence of some distress and or inter-
ference with activities beyond completion of chemother-
apy. At 9 months signiﬁcantly more distress/interference
was observed due to tingling hands/feet and nail
changes in the FEC-D group and to tiredness in the con-
trol group. Diﬀerences between the regimens resolved by
24 months. Centre’s choice of control regimen was not a
signiﬁcant factor in analyses at 9 and 24 months.
4. Discussion
The ﬁndings of this large study of QL and toxicity
provide clear evidence of women’s experience of greater
toxicity and disruption to diverse aspects of their QL
over many months from taxane-containing treatment
compared to standard adjuvant chemotherapy. Whilst
established QL subscales provide broad coverage,
details of the impact of toxicity are better reﬂected using
the diary card approach. These results build usefully on
the well-established but more limited reporting of
adverse eﬀects in other such clinical trials [3–10], TACT
patients were able to report not only the severity and
duration of side eﬀects, but also the unique distress
and disruption to daily life that each symptom caused.
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Fig. 4. Diary card: Proportion experiencing side eﬀect ‘quite a bit’ or ‘very much’ during treatment by regimen. P-values compare area under the curve by Mann–Whitney U test. Note scale of vertical
axis diﬀers on each row.
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Table 2
Diary card ratings of side eﬀect experience, distress and interference with activities: proportion rating as ‘quite a bit’/’very much’.
Side Eﬀect Cycle 1 Cycle 5 Cycle 8 9 Months 12 Months 18 Months 24 Months
Control FEC-D Control FEC-D Control FEC-D Control FEC-D ontrol FEC-D Control FEC-D Control FEC-D
N = 226 N = 254 N = 226 N = 258 N = 219 N = 240 N = 321 N = 334 = 314 N = 342 N = 293 N = 311 N = 287 N = 293
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) (%) n (%) n (%) n (%) n (%) n (%)
Nausea Experience 108 (47.8) 134 (52.8) 103 (45.6) 41 (15.9) 79 (36.1) 35 (14.6)
Distress 60 (26.5) 79 (31.1) 58 (25.7) 20 (7.8) 39 (17.8) 15 (6.3) 12 (3.7) 15 (4.5) (2.9) 6 (1.8) 6 (2.0) 3 (1.0) 1 (0.3) 6 (2.0)
Interference 63 (27.9) 75 (29.5) 53 (23.5) 17 (6.6) 35 (16.0) 14 (5.8) 9 (2.8) 7 (2.1) (1.9) 3 (0.9) 6 (2.0) 4 (1.3) 1 (0.3) 4 (1.4)
Vomiting Experience 44 (19.5) 73 (28.7) 36 (15.9) 22 (8.5) 33 (15.1) 11 (4.6)
Distress 34 (15.0) 58 (22.8) 29 (12.8) 10 (3.9) 18 (8.2) 4 (1.7) 4 (1.2) 2 (0.6) (1.0) 2 (0.6) 2 (0.7) 2 (0.6) 0 (0) 2 (0.7)
Interference 36 (15.9) 55 (21.7) 23 (10.2) 7 (2.7) 19 (8.7) 4 (1.7) 5 (1.6) 1 (0.3) (1.3) 1 (0.3) 3 (1.0) 1 (0.3) 1 (0.3) 4 (1.4)
Skin Experience 26 (11.5) 24 (9.4) 22 (9.7) 63 (24.4) 18 (8.2) 67 (27.9)
Distress 5 (2.2) 7 (2.8) 6 (2.7) 30 (11.6) 7 (3.2) 26 (10.8) 30 (9.3) 37 (11.1) (4.5) 18 (5.3) 14 (4.8) 14 (4.5) 17 (5.9) 13 (4.4)
Interference 1 (0.4) 5 (2.0) 2 (0.9) 14 (5.4) 5 (2.3) 4 (1.7) 8 (2.5) 11 (3.3) (1.3) 5 (1.5) 4 (1.4) 5 (1.6) 8 (2.8) 6 (2.0)
Tingling/numb hands/
feet
Experience 12 (5.3) 10 (3.9) 12 (5.3) 76 (29.5) 17 (7.8) 100 (41.7)
Distress 4 (1.8) 3 (1.2) 5 (2.2) 29 (11.2) 10 (4.6) 56 (23.3) 29 (9.0) 75 (22.5) (10.5) 45 (13.2) 26 (8.9) 28 (9.0) 25 (8.7) 27 (9.2)
Interference 1 (0.4) 0 (0) 4 (1.8) 26 (10.1) 6 (2.7) 32 (13.3) 20 (6.2) 34 (10.2) (5.7) 22 (6.4) 13 (4.4) 13 (4.2) 10 (3.5) 12 (4.1)
Tiredness Experience 140 (61.9) 182 (71.7) 165 (73) 216 (83.7) 161 (73.5) 207 (86.3)
Distress 55 (24.3) 79 (31.1) 83 (36.7) 128 (49.6) 80 (36.5) 114 (47.5) 94 (29.3) 83 (24.9) (20.4) 57 (16.7) 61 (20.8) 59 (19) 54 (18.8) 46 (15.7)
Interference 78 (34.5) 102 (40.2) 106 (46.9) 147 (57.0) 85 (38.8) 129 (53.8) 94 (29.3) 69 (20.7) (18.5) 44 (12.9) 48 (16.4) 37 (11.9) 44 (15.3) 43 (14.7)
Diarrhoea Experience 26 (11.5) 31 (12.2) 35 (15.5) 74 (28.7) 41 (18.7) 51 (21.3)
Distress 10 (4.4) 11 (4.3) 10 (4.4) 40 (15.5) 19 (8.7) 17 (7.1) 9 (2.8) 10 (3.0) (1.9) 6 (1.8) 6 (2.0) 9 (2.9) 11 (3.8) 5 (1.7)
Interference 5 (2.2) 8 (3.1) 10 (4.4) 31 (12.0) 16 (7.3) 12 (5.0) 4 (1.2) 6 (1.8) (1.0) 2 (0.6) 5 (1.7) 6 (1.9) 7 (2.4) 4 (1.4)
Constipation Experience 62 (27.4) 86 (33.9) 56 (24.8) 64 (24.8) 56 (25.6) 53 (22.1)
Distress 25 (11.1) 35 (13.8) 28 (12.4) 32 (12.4) 27 (12.3) 24 (10.0) 16 (5.0) 16 (4.8) (3.5) 5 (1.5) 9 (3.1) 10 (3.2) 16 (5.6) 5 (1.7)
Interference 11 (4.9) 21 (8.3) 16 (7.1) 21 (8.1) 9 (4.1) 13 (5.4) 7 (2.2) 7 (2.1) (1.3) 4 (1.2) 5 (1.7) 6 (1.9) 9 (3.1) 2 (0.7)
Sore mouth Experience 31 (13.7) 37 (14.6) 49 (21.7) 144 (55.8) 58 (26.5) 87 (36.3)
Distress 18 (8.0) 20 (7.9) 29 (12.8) 100 (38.8) 31 (14.2) 53 (22.1) 8 (2.5) 20 (6.0) (1.6) 9 (2.6) 7 (2.4) 7 (2.3) 10 (3.5) 7 (2.4)
Interference 6 (2.7) 12 (4.7) 24 (10.6) 61 (23.6) 16 (7.3) 29 (12.1) 9 (2.8) 12 (3.6) (1.3) 5 (1.5) 4 (1.4) 4 (1.3) 6 (2.1) 5 (1.7)
Mouth ulcers Experience 12 (5.3) 18 (7.1) 28 (12.4) 59 (22.9) 36 (16.4) 35 (14.6)
Distress 8 (3.5) 15 (5.9) 17 (7.5) 50 (19.4) 27 (12.3) 29 (12.1) 4 (1.2) 14 (4.2) (1.0) 6 (1.8) 6 (2.0) 5 (1.6) 5 (1.7) 7 (2.4)
Interference 1 (0.4) 8 (3.1) 12 (5.3) 32 (12.4) 17 (7.8) 16 (6.7) 7 (2.2) 11 (3.3) (1.0) 5 (1.5) 6 (2.0) 4 (1.3) 2 (0.7) 4 (1.4)
Breathlessness Experience 15 (6.6) 22 (8.7) 38 (16.8) 53 (20.5) 61 (27.9) 72 (30.0)
Distress 11 (4.9) 15 (5.9) 27 (11.9) 41 (15.9) 31 (14.2) 54 (22.5) 27 (8.4) 25 (7.5) (8.0) 17 (5.0) 19 (6.5) 13 (4.2) 18 (6.3) 16 (5.5)
Interference 10 (4.4) 17 (6.7) 28 (12.4) 40 (15.5) 37 (16.9) 57 (23.8) 28 (8.7) 23 (6.9) (7.3) 19 (5.6) 15 (5.1) 11 (3.5) 19 (6.6) 14 (4.8)
Swollen hands/feet Experience 6 (2.7) 11 (4.3) 27 (11.9) 49 (19.0) 31 (14.2) 82 (34.2)
Distress 3 (1.3) 2 (0.8) 9 (4.0) 19 (7.4) 13 (5.9) 39 (16.3) 37 (11.5) 54 (16.2) (11.8) 33 (9.6) 22 (7.5) 32 (10.3) 23 (8.0) 19 (6.5)
Interference 1 (0.4) 3 (1.2) 9 (4.0) 14 (5.4) 12 (5.5) 28 (11.7) 21 (6.5) 33 (9.9) (8.3) 17 (5.0) 16 (5.5) 19 (6.1) 17 (5.9) 10 (3.4)
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yFor instance, nail changes, swollen and/or tingling
hands or feet may be regarded clinically as manageable
or of nuisance value, but were not only more prevalent,
and distressing but also interfered more with daily life in
women receiving FEC-D than those treated with stan-
dard regimens. This supports evidence from smaller
studies exploring more speciﬁc taxane toxicities [4,28–
30], and may help explain delayed emotional recovery,
reduced compliance or early discontinuation of taxane
containing chemotherapy [31,32]. The introduction of
TACT diary cards gave unique insights into the impact
of adjuvant chemotherapy; to our knowledge similar
ﬁndings have not previously been reported in an adju-
vant breast cancer clinical trial.
Assessment of multiple QL domains highlighted the
social, psychological and physical reality of undergoing
adjuvant chemotherapy, with worsening and improve-
ment in these domains mirroring that of toxicity. Most
functional and psychosocial domains as well as side
eﬀects reduced substantially after the end of treatment.
Exceptions were slow recovery of body image and sexual
function and persistent tiredness and joint pains, irre-
spective of regimen, possibly secondary to changes in
hormonal status. The onset of a menopause after che-
motherapy is an important survivorship concern [33],
whilst younger patients report both more menopausal
concerns [34] and greater concerns about fertility than
age matched controls [35]. Women in the TACT trial
who underwent a menopausal transition may have expe-
rienced such concerns and so clinical teams need to dis-
tinguish QL issues due to these problems in order to give
appropriate support and advice.
It is implicit in QL evaluation that ﬁndings will be
taken into account in trial outcomes and translated into
clinical practice. Together with the TACT clinical results
[2] these ﬁndings can aid clinicians’ discussion with
patients. The indication to use taxanes in combination
with trastuzumab or similar agents means that a sub-
stantial minority of women will be exposed to this
increased toxicity. Moreover, appropriate support and
advice are needed to mitigate distress and optimise side
eﬀect management. Similar considerations exist for
women with metastatic disease where the burden of tox-
icity must be balanced against treatment eﬃcacy in the
palliative setting.
Our ﬁndings were consistent across QL domains but
interpretation may be aﬀected by several factors. Eighty-
eight (21.2%) controls and 66 (15.9%) FEC-D patients
stopped treatment early; the majority of those in the
FEC-D group received at least one taxane cycle but
had higher systemic side eﬀect scores than those com-
pleting treatment. Control group patients stopping early
had slightly lower side eﬀect scores than those complet-
ing treatment but diﬀerences between these subgroups
were not clinically relevant. Diary cards discriminated
well between the treatment regimens but completion
Table 3
Odds ratios (OR) for diary card reports of side eﬀect experience, distress and interference with activities as ‘quite a bit’ or ’very much’.
Cycle 8 9 Months 24 Months
OR (99% CI) P-value OR (99% CI) P lue OR (99% CI) P-value
Nausea Experience 0.30 (0.16, 0.56) <0.0001
Distress 0.30 (0.13, 0.70) 0.0001 1.22 (0.44, 3.36) 0. 5.98 (0.36, 98.04) 0.06
Interference 0.32 (0.13, 0.76) 0.0004 0.75 (0.20, 2.80) 0. 3.91 (0.22, 69.63) 0.19
Vomiting Experience 0.27 (0.10, 0.69) 0.0001
Distress 0.19 (0.05, 0.81) 0.001 0.48 (0.05, 4.42) 0. –* (–, –) 0.16
Interference 0.18 (0.04, 0.76) 0.0005 0.19 (0.01, 3.18) 0. 3.97 (0.22, 73.31) 0.19
Skin Experience 4.34 (2.02, 9.31) <0.0001
Distress 3.87 (1.24, 12.05) 0.001 1.21 (0.62, 2.36) 0. 0.73 (0.27, 1.94) 0.4
Interference 0.77 (0.13, 4.45) 0.7 1.35 (0.40, 4.61) 0. 0.72 (0.18, 2.98) 0.55
Tingling/numb hands/feet Experience 8.76 (3.90, 19.66) <0.0001
Distress 7.01 (2.65, 18.52) <0.0001 2.89 (1.56, 5.34) < 001 1.07 (0.51, 2.25) 0.82
Interference 5.92 (1.78, 19.68) <0.0001 1.73 (0.81, 3.70) 0. 1.17 (0.38, 3.61) 0.72
Tiredness Experience 2.40 (1.25, 4.61) 0.0004
Distress 1.73 (1.03, 2.90) 0.006 0.80 (0.50, 1.26) 0. 0.80 (0.45, 1.42) 0.32
Interference 2.09 (1.23, 3.54) 0.0002 0.63 (0.39, 1.00) 0. 0.94 (0.51, 1.71) 0.78
Diarrhoea Experience 1.19 (0.65, 2.17) 0.46
Distress 0.85 (0.35, 2.07) 0.64 1.05 (0.31, 3.54) 0. 0.44 (0.11, 1.78) 0.12
Interference 0.71 (0.26, 1.93) 0.37 1.42 (0.26, 7.60) 0. 0.55 (0.11, 2.80) 0.34
Constipation Experience 0.83 (0.47, 1.47) 0.4
Distress 0.79 (0.37, 1.71) 0.43 0.96 (0.38, 2.43) 0. 0.29 (0.08, 1.13) 0.01
Interference 1.37 (0.43, 4.31) 0.48 0.94 (0.23, 3.83) 0. 0.21 (0.03, 1.61) 0.03
Sore mouth Experience 1.60 (0.94, 2.71) 0.02
Distress 1.80 (0.94, 3.45) 0.02 2.51 (0.84, 7.52) 0. 0.68 (0.19, 2.45) 0.44
Interference 1.85 (0.79, 4.35) 0.06 1.27 (0.41, 3.99) 0. 0.81 (0.17, 3.93) 0.73
Mouth ulcers Experience 0.88 (0.45, 1.72) 0.63
Distress 0.99 (0.47, 2.08) 0.98 3.51 (0.80, 15.47) 0. 1.38 (0.30, 6.34) 0.58
Interference 0.87 (0.34, 2.22) 0.69 1.55 (0.44, 5.47) 0. 1.94 (0.21, 18.32) 0.44
Breathlessness Experience 1.11 (0.65, 1.90) 0.61
Distress 1.91 (0.99, 3.68) 0.009 0.88 (0.42, 1.86) 0. 0.86 (0.35, 2.12) 0.66
Interference 1.68 (0.91, 3.12) 0.03 0.77 (0.36, 1.65) 0. 0.70 (0.27, 1.77) 0.31
Swollen hands/feet Experience 3.17 (1.69, 5.94) <0.0001
Distress 3.35 (1.39, 8.04) 0.0002 1.49 (0.82, 2.69) 0. 0.79 (0.35, 1.83) 0.48
Interference 2.50 (0.98, 6.37) 0.009 1.55 (0.73, 3.30) 0. 0.55 (0.19, 1.59) 0.14
Nail changes Experience 7.58 (3.77, 15.26) <0.0001
Distress 7.36 (3.04, 17.79) <0.0001 3.06 (1.73, 5.39) < 001 0.91 (0.35, 2.37) 0.81
Interference 9.69 (2.32, 40.58) <0.0001 2.99 (1.18, 7.58) 0. 1 0.43 (0.10, 1.77) 0.11
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low-up: administrative problems may have contributed.
It should be noted that statistically signiﬁcant diﬀerences
between the experimental and control regimens may not
necessarily be clinically relevant. Strengths of this study
include the large sample size and the low level of attri-
tion together with detailed and novel reporting of treat-
ment side eﬀects.
It has been reported that doctors ‘underestimate’
patients’ symptoms and distress and therefore patient
reported outcomes are more ‘accurate’, however medical
assessments andpatients’ ratings are drawn fromdiﬀerent
contexts and are not interchangeable [11,12,36,37]. Bio-
medical and psychosocial perspectives are complemen-
tary [38–40], both providing valuable insights into the
treatment experience. This is particularly relevant when
considering regimens where the trade-oﬀ between toxicity
and beneﬁt is small, uncertain or absent. Therefore equal
emphasis to the patients’ and clinicians’ perspectives can
provide optimal care for women undergoing adjuvant
chemotherapy. As indications for the use of taxanes in
the management of early breast cancer evolve the trade-
oﬀ between clinical beneﬁt and QL will need to be reas-
sessed both in randomised controlled trials and in the
decision making process for individual patients.Funding
The research costs of the trial were met by Cancer
Research UK (CRUK 01/001) and by educational
grants from Sanoﬁ-Aventis, Pﬁzer and Roche. We
acknowledge NHS funding to the NIHR Biomedical
Research Centre at The Royal Marsden NHS Founda-
tion Trust and The Institute of Cancer Research,
London.Authors contributions
P Hopwood was responsible for the design and man-
agement of the QL sub-study, clinical data interpreta-
tion and manuscript writing. E Hall was responsible
for study design, trial management, statistical data inter-
pretation, manuscript writing and oversaw all statistical
analyses. D Cameron was responsible for the design of
the QL sub-study and manuscript writing and contrib-
uted to data interpretation. P Ellis and P Barrett-Lee
were joint Chief Investigators of the main TACT trial
and contributed to study design, data interpretation
and manuscript writing. J M Bliss was responsible for
study design, trial management, data interpretation,
contributed to manuscript writing and oversaw all sta-
tistical analyses. R Waters conducted the statistical anal-
yses. S Crawford was responsible for trial management
and data collection. All authors contributed to manu-
script review.
2388 E. Hall et al. / European Journal of Cancer 50 (2014) 2375–2389Conﬂict of interest statement
None declared.Acknowledgments
Grateful thanks are due to all the patients who partic-
ipated in this study. Recruitment was supported by the
National Institute for Health Research Clinical
Research Network. We thank all staﬀ at TACT QL
centres, and trials unit staﬀ at Information Services
Division Edinburgh (formerly (SCTN)), Clinical Trials
Research Unit, Leeds, Wales Cancer Trials Network
(WCTN), Cardiﬀ, CRUK & UCL Cancer Trials Centre,
London and The Institute of Cancer Research’s Clinical
Trials & Statistics Unit (ICR-CTSU) who contributed
to the study management and data collection with spe-
cial thanks to L Johnson (ICR-CTSU), N Atkins
(ICR-CTSU) and J Morden (ICR-CTSU). The authors
acknowledge the contributions of their past and present
colleagues on the Trial Management Group (TMG) and
thank the independent data monitoring committee and
trial steering committee for their oversight of the trial.
Appendix A. Supplementary data
Supplementary data associated with this article,
including a list of TMG members and contributers to
the TACT QL study can be found, in the online version,
at http://dx.doi.org/10.1016/j.ejca.2014.06.007.
References
[1] Early Breast Cancer Trialists Collaborative Group (EBCTCG),
Peto R, Davies C, Godwin J, Gray R, Pan HC, et al. Compar-
isons between diﬀerent polychemotherapy regimens for early
breast cancer: meta-analyses of long-term outcome among
100,000 women in 123 randomised trials. Lancet 2012;
379(9914):432–44.
[2] Ellis P, Barrett-Lee P, Johnson L, Cameron D, et al. Sequential
docetaxel as adjuvant chemotherapy for early breast cancer
(TACT): an open label, phase 111, randomised controlled trial.
Lancet 2009;373(9676):1681–92.
[3] Francis P, Crown J, Di Leo A, Buyse M, Balil A, Andersson M,
et alBIG 02-98 Collaborative Group. Adjuvant chemotherapy
with sequential or concurrent anthracycline and docetaxel: Breast
International Group 02–98 randomized trial. J Natl Cancer Inst
2008;100:121–33.
[4] Jones S, Holmes FA, O’Shaughnessy J, Blum JL, Vukelja SJ,
McIntyre KJ, et al. Docetaxel with cyclophosphamide is associ-
ated with an overall survival beneﬁt compared with doxorubicin
and cyclophosphamide: 7 year follow-up of US Oncology
Research Trial 9735. J Clin Oncol 2009;27(8):1177–83.
[5] Mamounas EP, Bryant J, Lembersky B, Fehrenbacher L,
Sedlacek SM, Fisher B, et al. Paclitaxel after doxorubicin plus
cyclophosphamide as adjuvant chemotherapy for node-positive
breast cancer: results from NSABP B28. J Clin Oncol
2005;23(16):3686–96.
[6] Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla J-P,
et al. Adjuvant docetaxel for node-positive breast cancer. N Engl
J Med 2005;352(22):2302–13.[7] Martin M, Lluch A, Seguı´ MA, Ruiz A, ADrover E, Rodrı´gue-
Lescure A´, et al. Toxicity and health-related quality of life in
breast cancer patients receiving adjuvant docetaxel, doxorubicin,
cyclophosphamide (TAC) or 5-ﬂuorouracil, doxorubicin and
cyclophosphamide (FAC): impact of adding primary granulo-
cyte-colony stimulating factor to the TAC regimen. Annals Oncol
2006;17:1205–12.
[8] Martin M, Rodrı´guez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-
Borrego M, et alGEICAM 9906 Study Investigators. Randomised
phase 3 trial of ﬂuorouracil, epirubicin and cyclophosphamide
alone or followed by paclitaxel for early breast cancer. J Natl
Cancer Inst 2008;100:805–14.
[9] Polyzos A, Malamos N, Boukovinas I, Adamou A, et al. FEC
versus sequential docetaxel followed by epirubicin/cyclophospha-
mide as adjuvant chemotherapy in women with axillary node-
positive early breast cancer: a randomised study of the Hellenic
Oncology research Group (HORG). Breast Cancer Res Treat
2010;119:95–104.
[10] Roche´ H, Fumoleau P, Spielmann M, Canon J-L, et al. Sequen-
tial adjuvant epirubicin-based and docetaxel chemotherapy for
node-positive breast cancer patients: the FNCLCC PACS 01
Trial. J Clin Oncol 2006;24(36):5664–71.
[11] Stephens RJ, Hopwood P, Girling DJ, Machin D. Randomised
trials with quality of life endpoints: Are doctors’ ratings of
patients’ physical symptoms interchangeable with patients’ self-
ratings? Qual Life Res 1997;6:225–36.
[12] Velikova G, Wright P, Smith AB, et al. Self-reported quality of
life of individual cancer patients: concordance of results with
disease course and medical records. J Clin Oncol
2001;19:2064–73.
[13] Werner A, Stenner C, Schu¨z J. Patient versus clinician symptoms
reporting: how accurate is the detection of distress in the
oncologic after-care? Psychooncology 2011;21(8):818–26.
[14] Groenvold M, Fayers PM, Petersen MA, Sprangers MA,
Aaronson NK, Mouridsen HT. Breast cancer patients on adju-
vant chemotherapy report a wide range of problems not identiﬁed
by health care staﬀ. Breast Cancer Res Treat 2007;103(2):185–95.
[15] Duric V, Stockler M. Patients’ preferences for adjuvant chemo-
therapy in early breast cancer: a review of what makes it
worthwhile? Lancet Oncol 2001;2:691–7.
[16] Duric VM, Butow PN, Sharpe L, Boyle F, Beith J, Wicken NR,
et al. Psychosocial factors and patients’ preferences for adjuvant
chemotherapy in early breast cancer. Psychooncology 2007;16(1):
48–9.
[17] Ganz PA, Rowland JH, Desmond K, Meyerowitz BE, Wyatt GE.
Life after breast cancer: understanding women’s health-related
quality of life and sexual functioning. J Clin Oncol
1998;16(2):501–14.
[18] Ganz PA. Menopause and breast cancer: symptoms, late eﬀects,
and their management. Semin Oncol 2001;28(3):274–83.
[19] Poole CJ, Earle HM, Hiller L, Dunn JA, et alNEAT Investigators
and the SCTBG. Epirubicin and cyclophosphamide, methotrexate
and ﬂuourouracil as adjuvant therapy for early breast cancer. N
Engl J Med 2006;355(18):1851–62.
[20] Aaronson NK, Ahmedzai S, Bergman B, et al. The European
Organization for Research and Treatment of Cancer QLQ-C30: a
quality-of-life instrument for use in international clinical trials in
oncology. J Natl Cancer Inst 1993;85:365–76.
[21] Sprangers MA, Groenvold M, Arraras JI, et al. The European
Organization for Research and Treatment of Cancer breast
cancer-speciﬁc quality-of-life questionnaire module: ﬁrst results
from a three-country ﬁeld study. J Clin Oncol 1996;10:2756–68.
[22] Zigmond AS, Snaith RP. The hospital anxiety and depression
scale. Acta Psychiatr Scand 1983;67:361–70.
[23] Fayers PM, Bleehen NM, Girling DJ, Steohens RJ. Assessment of
quality of life in small-cell lung cancer using a Daily Diary Card
developed by the Medical research Council Lung Cancer Working
Party. Br J Cancer 1991;64:299–306.
E. Hall et al. / European Journal of Cancer 50 (2014) 2375–2389 2389[24] Medical Research Council Lung Cancer Working Party. Con-
trolled trial of 12 versus 6 courses of chemotherapy in the
treatment of small-cell lung cancer. Br J Cancer 1989;59:584.
[25] Fayers PM, Aaronson N, Bjordal K. EORTC QLQ-C30 scoring
manual, on behalf of the EORTC Quality of Life Study Group.
3rd ed; 2001.
[26] Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the
signiﬁcance of changes in health-related quality of life scores. J
Clin Oncol 1998;16:139–44.
[27] Williams R. Generalized ordered logit/ partial proportional odds
models for ordinal dependent variables. Stata J 2006;6(1):58–82.
[28] Eckhoﬀ L, Nielsen M, Moeller S, Knoop A. TAXTOX – a
retrospective study regarding the side eﬀects of docetaxel given as
part of adjuvant treatment to patients with primary breast cancer
in Denmark from 2007 to 2009. Acta Oncol 2011;50(7):1075–82.
[29] Hackbarth M, Haas N, Fotopoulou C, Lichtenegger W, Sehouli
J. Chemotherapy-induced dermatological toxicity: frequencies
and impact on quality of life in women’s cancers. Results of a
prospective study. Support Care Cancer 2008;16(3):267–73.
[30] Hershman DL, Weimer LH, Wang A, Kranwinkel G, Brafman L,
Fuentes D, et al. Association between patient reported outcomes
and quantitative sensory tests for measuring long-term neurotox-
icity in breast cancer survivors treated with adjuvant paclitaxel
chemotherapy. Breast Cancer Res Treat 2011;125:767–74.
[31] Winther D, Saunte DM, Knap M, Haahr V, Jensen AB. Nail
changes due to docetaxel – a neglected side eﬀect and nuisance for
the patient. Support Care cancer 2007;15:1191–7.
[32] Thornton LM, Carson III WE, Shapiro CL, Farrar WB,
Anderson BL. Delayed emotional recovery after taxane-based
chemotherapy. Cancer 2008;113:638–47.
[33] Ganz PA, Land SR, Geyer Jr CE, Cecchini RS, Constantino JP,
Pajon ER, et al. Menstrual history and quality-of-life outcomes inwomen with node-positive breast cancer treated with adjuvant
therapy on the NSABP B-30 Trial. J Clin Oncol
2011;29(9):1110–6.
[34] Ruddy KJ, Gelber S, Gunsburg ES, Schapira LS, Abusief ME,
Meyer ME, et al. Menopausal symptoms and fertility concerns in
premenopausal breast cancer survivors: a comparison to age-and
gravidity-matched controls. Menopause 2011;18(1):105–8.
[35] Anderson DL, Yates P, McCarthy A, Lang CP, McCarthy N,
Porter-Steele J. Younger and older women’s concerns about
menopause after breast cancer. Eur J Cancer Care 2011;20(6):
785–94.
[36] Fromme EK, Eilers KM, Mori M, Hsieh Y-C, Beer TM. How
accurate is clinician reporting of chemotherapy adverse eﬀects? A
comparison with patient-reported symptoms from the Quality of
Life Questionnaire C30. J Clin Oncol 2004;22(17):3485–90.
[37] Takeuchi EE, Keding A, Awad N, Hofmann U, Campbell LJ,
Selby PJ, et al. Impact of patient-reported outcomes in oncology:
a longitudinal analysis of patient-physician communication. J
Clin Oncol 2011;29(21):2910–7.
[38] Basch E, Iasonas A, McDonough T, Barz A, Culkin A, Kris MG,
et al. Patient vs clinician symptoms reporting using the National
Cancer Institute Common Terminology Criteria for Adverse
events: results of a questionnaire-based study. Lancet Oncol
2006;7:903–9.
[39] Gotay C. Patient symptoms and clinician toxicity ratings: both
have a role in cancer care. JNCI 2009;101(23):1602–3.
[40] Quinten C, Maringwa J, Gotay CC, Martinelli F, Coens C, Reeve
BB, et al. Patient self-reports of symptoms and clinician ratings
as predictors of overall cancer survival. J Natl Cancer Inst
2011;103:1851–8.
